Novel Compstatin Analogs for the Treatment of Inflammatory and Autoimmune Diseases

Tech ID: 24322 / UC Case 2012-461-0

Brief Description

Background:

Inappropriate complement activation may cause or aggravate several pathological conditions, such as age-related macular degeneration, asthma, adult respiratory distress syndrome, chronic obstructive pulmonary diseases, hemolytic anemia, rare kidney diseases, lupus, rheumatoid arthritis, rejection of xenotransplantation, stroke and heart attack. Regulating complement activation is important to control inflammation, autoimmune diseases, and infections. Peptides of the compstatin family inhibit complement system activation and are promising candidates to become therapeutics for the treatment of complement-related diseases and disorders.

Description:

UCR researchers and their collaborators from Princeton University and the University of Cyprus have developed novel compstatin analogs that lead to the future development of therapeutics for age-related macular degeneration and other complement system-mediated diseases.  The new peptides target the complement system protein C3, they are potent in terms of required binding affinity, and have improved solubility compared to previously known compstatin peptides. 

Images

boo

Image:

The backbone of a potent compstatin peptide (red tube and colored stick model) bound on the surface of the immune system protein C3. Five regions of peptide-protein interactions are shown in different colors. The molecular graphics is generated using three-dimensional coordinates from a molecular dynamics simulation trajectory.

Advantages

  • Targeting of protein C3, the converging point of complement activation pathways
  • Potent binding affinity
  • Higher solubility compared to previously known potent compstatin analogs


Applications

  • Therapeutics for age-related macular degeneration and rare diseases, e.g. paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and dense deposit disease (DDD)
  • Therapeutics for other complement system-mediated inflammatory and autoimmune diseases, e.g. chronic obstructive pulmonary disease, systemic lupus erythematosus, rheumatoid arthritis, and ischemia reperfusion injuries

Patent Status

Country Type Number Dated Case
United States Of America Issued Patent 9,512,180 12/06/2016 2012-461
 

Contact

Learn About UC TechAlerts - Save Searches and receive new technology matches

Other Information

Keywords

Complement system, Compstatin, C3, Complement system-mediated diseases, Autoimmune Diseases

Categorized As